Eyenovia re-acquires development and commercialization rights to micropine in the u.s. and canada

Micropine, currently in late phase iii for pediatric progressive myopia, to complement eyenovia's commercial-stage asset, mydcombi, as well as its pre-pdufa candidate, app13007

EYEN Ratings Summary

EYEN Quant Ranking